2022
DOI: 10.3390/bios12100847
|View full text |Cite
|
Sign up to set email alerts
|

An Asymmetric Microfluidic/Chitosan Device for Sustained Drug Release in Guided Bone Regeneration Applications

Abstract: One of the major challenges of guided bone regeneration (GBR) is infections caused by pathogen colonization at wound sites. In this paper, an asymmetric microfluidic/chitosan device was developed to release drugs to inhibit infections and to ensure that guided bone regeneration can be realized. The microfluidic technique was introduced into the GBR membrane for the first time, which demonstrated more controllable drug release, more flexible clinical use and had a lower cost compared with surface treatments and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 39 publications
0
3
0
Order By: Relevance
“…The avail of chitosan nanoparticles as nanocarriers can provide additional antimicrobial benefits. 189 5.5. Iron Oxide Nanoparticles.…”
Section: Polymeric Nanoparticles (Nps)mentioning
confidence: 99%
See 1 more Smart Citation
“…The avail of chitosan nanoparticles as nanocarriers can provide additional antimicrobial benefits. 189 5.5. Iron Oxide Nanoparticles.…”
Section: Polymeric Nanoparticles (Nps)mentioning
confidence: 99%
“…Chitosan has inherent antibacterial properties, that can help prevent infections around bone regeneration. The avail of chitosan nanoparticles as nanocarriers can provide additional antimicrobial benefits …”
Section: Nanocarriers For Drug Delivery In Bone Regenerationmentioning
confidence: 99%
“…Pathogen infection is the major challenge affecting guided bone regeneration. Shi et al [21] developed an asymmetric microfluidic/chitosan device for releasing drugs so as to prevent infections and guide bone regeneration. Their device achieved the controllable drug release (the deviation of the minocycline release was only 12.7% over 5 days).…”
mentioning
confidence: 99%